Douedi Steven, Chaudhri Moiuz, Miskoff Jeffrey
Department of Medicine, Hackensack Meridian Health, Jersey Shore University Medical Center, Neptune, NJ, USA.
Department of Pulmonary and Critical Care, Hackensack Meridian Health, Jersey Shore University Medical Center, Neptune, NJ, USA.
Ann Thorac Med. 2020 Jul-Sep;15(3):171-173. doi: 10.4103/atm.ATM_286_20. Epub 2020 Jun 18.
Novel coronavirus disease 2019 (COVID-19) is known to cause severe pneumonia and acute respiratory distress syndrome which may lead to death. Several treatments have been tested in the race to find a treatment regimen for this deadly viral infection. Tocilizumab, a recombinant humanized anti-interleukin-6 receptor monoclonal antibody, has been used and found to be beneficial in patients with COVID-19 and in cytokine storm. We present the case of a young, otherwise healthy male, presenting with COVID-19 and successfully treated in the intensive care unit with tocilizumab.
新型冠状病毒肺炎（COVID-19）已知会导致严重肺炎和急性呼吸窘迫综合征，这可能会导致死亡。在寻找针对这种致命病毒感染的治疗方案的竞赛中，已经对几种治疗方法进行了测试。托珠单抗是一种重组人源化抗白细胞介素-6受体单克隆抗体，已被用于治疗COVID-19患者，并被发现对细胞因子风暴有益。我们报告了一例年轻、身体健康的男性COVID-19患者，在重症监护病房接受托珠单抗治疗并成功治愈的病例。
